AbbVie Company Profile (NYSE:ABBV)

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Specialty & Advanced Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ABBV
  • CUSIP: 00287Y10
  • Web:
  • Market Cap: $115.77 billion
  • Outstanding Shares: 1,591,540,000
Average Prices:
  • 50 Day Moving Avg: $67.41
  • 200 Day Moving Avg: $64.18
  • 52 Week Range: $55.06 - $72.94
  • Trailing P/E Ratio: 18.86
  • Foreward P/E Ratio: 11.14
  • P/E Growth: 0.91
Sales & Book Value:
  • Annual Revenue: $26.22 billion
  • Price / Sales: 4.42
  • Book Value: $3.14 per share
  • Price / Book: 23.17
  • Annual Dividend: $2.56
  • Dividend Yield: 3.5%
  • EBIDTA: $11.15 billion
  • Net Margins: 24.07%
  • Return on Equity: 148.83%
  • Return on Assets: 12.18%
  • Debt-to-Equity Ratio: 7.31%
  • Current Ratio: 1.76%
  • Quick Ratio: 1.60%
  • Average Volume: 5.55 million shs.
  • Beta: 1.52
  • Short Ratio: 5.37

Frequently Asked Questions for AbbVie (NYSE:ABBV)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Friday, June 23rd. Shareholders of record on Friday, July 14th will be paid a dividend of $0.64 per share on Tuesday, August 15th. This represents a $2.56 annualized dividend and a yield of 3.52%. The ex-dividend date is Wednesday, July 12th. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie declared that its Board of Directors has initiated a share repurchase program on Sunday, April 9th 2017, which permits the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase up to 5% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board of directors believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings results on Thursday, April, 27th. The company reported $1.28 earnings per share for the quarter, topping the Zacks' consensus estimate of $1.26 by $0.02. The business had revenue of $6.54 billion for the quarter, compared to analysts' expectations of $6.49 billion. AbbVie had a return on equity of 148.83% and a net margin of 24.07%. The business's quarterly revenue was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.15 earnings per share. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie updated its FY17 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $5.44-5.54 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.49.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

13 equities research analysts have issued 12 month price objectives for AbbVie's stock. Their predictions range from $60.00 to $90.00. On average, they expect AbbVie's share price to reach $73.42 in the next year. View Analyst Ratings for AbbVie.

What are analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)
  • 2. According to Zacks Investment Research, "AbbVie’s key drug Humira has been performing well and sales should continue to be driven by growing awareness, favorable clinical data, additional indications and expansion into new markets. Moreover, products like Viekira and Imbruvica have diversified AbbVie’s revenue base. Imbruvica has multi-billion dollar potential and AbbVie is exploring the potential to expand Imbruvica’s label into solid tumors and autoimmune diseases. AbbVie has a deep and promising pipeline and is also working on expanding its portfolio though additional deals. However, Viekira is facing intense pricing pressure and competition in the HCV market. Additionally, quite a few companies are working on bringing Humira biosimilars to market. Amgen’s biosimilar version of Humira received FDA approval in Sep 2016. Abbvie could see some of its dominant share in the arthritis market contract when Amgen’s new drug is launched." (9/28/2016)
  • 3. Argus analysts commented, "strong" second quarter earnings print.The analysts noted that not only were AbbVie's results driven by sales of Humira and Imbruvica, but its pipeline also "strengthened" following the acquisition of Stemcentrix and a partnership with Boehringer Ingelheim for the commercial rights of a new immunology drug that is in a late stage trial.The analysts also stated that the earnings print confirmed Imbruvica's "rapid acceptance" which bodes well for future sales. Coupled with the Venclexta drug, AbbVie boasts two "powerful drugs" to treat first- and second-line CLL and other hematogical malignancies.Related Link: Investors Cheer AbbVie's Q2 Numbers, ForecastThe analysts also stated that AbbVie's stock is "attractively valued" at just 11.2x their 2017 earnings per share estimate, which is "well below" the average multiple of 14.5 of other companies under Argus' coverage.Finally, the analysts boosted their full-year 2016 adjusted earnings per share estimate to $4.84 from $4.80 and their 2017 earnings per share estimate to $5.95 from $5.90."The company has strengthened its product portfolio and pipeline through several deals over the past 12 months, and continues to post strong sales of Humira, aided by new indications," (8/8/2016)

Are investors shorting AbbVie?

AbbVie saw a decrease in short interest in the month of May. As of May 15th, there was short interest totalling 30,327,253 shares, a decrease of 7.1% from the April 28th total of 32,651,310 shares. Based on an average daily volume of 5,390,470 shares, the short-interest ratio is currently 5.6 days. Approximately 1.9% of the company's stock are sold short.

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

  • Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer
  • William J. Chase, Executive Vice President, Chief Financial Officer
  • Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer
  • Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary
  • Carlos Alban, Executive Vice President - Commercial Operations
  • Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer
  • Timothy J. Richmond, Senior Vice President - Human Resources
  • Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations
  • Robert A. Michael, Vice President, Controller
  • Robert J. Alpern M.D., Independent Director

Who owns AbbVie stock?

AbbVie's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.58%), Bank of New York Mellon Corp (1.14%), Morgan Stanley (0.00%) and State Farm Mutual Automobile Insurance Co. (0.00%). Company insiders that own AbbVie stock include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Janus Capital Management LLC, Glenview Capital Management LLC, Bank of New York Mellon Corp, APG Asset Management N.V., Miller Howard Investments Inc. NY, Parametric Portfolio Associates LLC, Fayez Sarofim & Co and Atalanta Sosnoff Capital LLC. Company insiders that have sold AbbVie stock in the last year include Carlos Alban, Laura J Schumacher, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Vanguard Group Inc., Renaissance Technologies LLC, State Street Corp, Prudential Financial Inc., Swiss National Bank and Atlantic Trust Group LLC. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $72.74.

MarketBeat Community Rating for AbbVie (NYSE ABBV)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  526 (Vote Outperform)
Underperform Votes:  248 (Vote Underperform)
Total Votes:  774
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for AbbVie (NYSE:ABBV) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 7 Hold Ratings, 5 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.54)
Consensus Price Target: $73.42 (0.93% upside)

Analysts' Ratings History for AbbVie (NYSE:ABBV)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/22/2017Leerink SwannReiterated RatingMarket PerformLowView Rating Details
6/22/2017Societe GeneraleUpgradeHold -> BuyLowView Rating Details
6/7/2017Credit Suisse GroupReiterated RatingHold$65.00MediumView Rating Details
5/26/2017Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
5/17/2017BMO Capital MarketsReiterated RatingMarket Perform$66.00LowView Rating Details
4/28/2017Deutsche Bank AGBoost Price TargetHold$64.00 -> $65.00LowView Rating Details
3/11/2017Goldman Sachs Group, Inc. (The)UpgradeBuy -> Conviction-Buy$74.00 -> $80.00N/AView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016Citigroup Inc.DowngradeBuy -> Neutral$60.00N/AView Rating Details
9/8/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$82.00N/AView Rating Details
8/8/2016ArgusReiterated RatingBuy$85.00N/AView Rating Details
8/2/2016Barclays PLCReiterated RatingEqual Weight$68.00N/AView Rating Details
6/8/2016Morgan StanleyDowngradeOverweight -> Equal Weight$73.00 -> $65.00N/AView Rating Details
6/6/2016Cowen and CompanyDowngradeOutperform -> Market Perform$77.00 -> $70.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00N/AView Rating Details
7/24/2015Evercore ISIReiterated RatingBuy$70.00N/AView Rating Details
7/22/2015SunTrust Banks, Inc.Initiated CoverageBuy$85.00N/AView Rating Details
(Data available from 6/26/2015 forward)


Earnings History for AbbVie (NYSE:ABBV)
Earnings by Quarter for AbbVie (NYSE:ABBV)
Earnings History by Quarter for AbbVie (NYSE ABBV)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.53 EPS
Next Year EPS Consensus Estimate: $6.53 EPS


Current Dividend Information for AbbVie (NYSE:ABBV)
Next Dividend:8/15/2017
Annual Dividend:$2.56
Dividend Yield:3.52%
Dividend Growth:12.50% (3 Year Average)
Payout Ratio:66.32% (Trailing 12 Months of Earnings)
46.29% (Based on This Year's Estimates)
39.20% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

Dividend History by Quarter for AbbVie (NYSE ABBV)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AbbVie (NYSE:ABBV)
Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 68.02%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.28View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.79View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.00View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.16View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.30View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.75View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.32View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.70View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.41View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for AbbVie (NYSE:ABBV)
Latest Headlines for AbbVie (NYSE:ABBV)
DateHeadline logoAbbVie Inc. (ABBV) Receives Consensus Recommendation of "Buy" from Brokerages - June 26 at 4:32 PM logoPfizer’s Xeljanz: Results from the ORAL Strategy - June 26 at 3:26 PM logoAbbVie Inc. (ABBV) Declares $0.64 Quarterly Dividend - June 23 at 7:58 PM logoAbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know - June 23 at 3:26 PM logoAbbVie Receives CHMP Positive Opinion for MAVIRET™ (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) - June 23 at 3:26 PM logo[$$] Samsung Makes Play for Drug Market With Version of Blockbuster Humira - June 23 at 3:26 PM logoAbbVie's Eagerly Anticipated Followup to Humira Is Coming: What You Need to Know - June 23 at 8:25 AM logoAbbVie Declares Quarterly Dividend - PR Newswire (press release) - June 23 at 4:34 AM logoTime To Buy Lagging Healthcare Stocks - June 22 at 11:34 PM logoAbbVie Inc. (ABBV) Stock Rating Reaffirmed by Leerink Swann - June 22 at 11:04 PM logoAbbVie Declares Quarterly Dividend - June 22 at 6:31 PM logoAbbVie Inc. (ABBV) Raised to "Buy" at Societe Generale - June 22 at 1:38 PM logoInside Vertex Pharmaceuticals’ Revenue Trend - June 22 at 1:28 PM logoBetter Buy: Pfizer Inc. vs. AbbVie Inc. - Nasdaq - June 21 at 3:21 PM logoAbbVie: A Wonderful Company But At What Price? - AbbVie Inc ... - Seeking Alpha - June 21 at 3:21 PM logoSo Much for Trump Going After Pharma - June 21 at 1:41 AM logoJ&J-AbbVie's Imbruvica Positive in Follow-up Lymphoma Study - June 20 at 8:39 PM logoBetter Buy: Pfizer Inc. vs. AbbVie Inc. - June 20 at 8:39 PM logoAbbVie (ABBV) Stock Hits 52-Week High: More Room to Run ... - Nasdaq - June 20 at 1:21 AM logoThe Case For A Pending Partnership Between Ani Pharmaceuticals And AbbVie - June 19 at 3:15 PM logoAs Clovis Oncology Soars, This Big Pharma Stock Clears New Buy Zone - June 19 at 3:15 PM logoETFs with exposure to AbbVie, Inc. : June 19, 2017 - June 19 at 3:15 PM logoAbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher - Motley Fool - June 18 at 3:16 PM logoAbbVie Stock Just Hit a 52-Week High: Here's Why It Should Go Even Higher - June 18 at 12:23 PM logoAbbVie Inc. (ABBV) Expected to Announce Quarterly Sales of $6.93 Billion - June 18 at 8:36 AM logoAbbVie, Inc. :ABBV-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 - June 16 at 8:20 PM logo$1.40 Earnings Per Share Expected for AbbVie Inc. (ABBV) This Quarter - June 16 at 6:06 PM logoAbbVie a Top Socially Responsible Dividend Stock With 3.6% Yield (ABBV) - June 15 at 8:10 PM logoHow Is AbbVie Expected to Perform in 2017? - June 15 at 8:10 PM logoThis Product Pipeline Brings Hope for AbbVie’s Future Growth - June 15 at 8:10 PM logoAbbVie Inc. (ABBV) EVP Sells $3,206,000.00 in Stock - June 15 at 7:26 PM logoLaura J. Schumacher Sells 79,800 Shares of AbbVie Inc. (ABBV) Stock - June 15 at 7:23 PM logoEpizyme's Positive Cancer Drug Results Likely to Catch the Eye of Celgene, J&J - June 15 at 3:08 PM logoVetr Inc. Lowers AbbVie Inc (ABBV) to Hold - June 15 at 12:44 AM logoHow AbbVie Inc. Makes Most of Its Money - Motley Fool - June 14 at 8:12 PM logoWhy AbbVie Is A 'Trump Stock' - June 14 at 3:11 PM logo[$$] Big US pharma dealmaking plunges to five-year low - June 13 at 3:15 PM logoHumira May Continue to Drive AbbVie’s Revenue Growth - June 13 at 3:15 PM logoImbruvica May Witness Significant Revenue Growth in 2017 - June 13 at 3:15 PM logoAn Overview of Imbruvica’s and Venclexta’s Clinical Pipelines - June 13 at 3:15 PM logoHow AbbVie Inc. Makes Most of Its Money - June 13 at 3:15 PM logoAbbVie and Principia Announce Collaboration on Oral Immunoproteasome Inhibitors - June 13 at 8:39 AM logoFirst bellwether over AbbVie's AndroGel ends in mistrial - Reuters - June 12 at 8:21 PM logoMoody's: Patent invalidation creates risk for US branded drug makers - June 12 at 3:19 PM logoAbbVie Inc (ABBV) Lifted to "Strong-Buy" at BidaskClub - June 10 at 11:12 PM logoAbbVie must pay $15 million in Depakote birth-defect trial: jury - June 10 at 8:15 PM logoWoman awarded $15 million from AbbVie after suing over Depakote drug - Reuters - June 9 at 3:17 PM logoAbbVie Ordered by Jury to Pay $15 Million to Depakote Victim - Bloomberg - June 9 at 3:17 PM logoAbbvie Vaults First Pivotal Hurdle With Oral RA Candidate - AbbVie ... - Seeking Alpha - June 9 at 3:17 PM logoWoman awarded $15 mln from AbbVie after suing over Depakote drug - June 9 at 3:17 PM



AbbVie (ABBV) Chart for Monday, June, 26, 2017

This page was last updated on 6/26/2017 by Staff